

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Pontifax Management 4 G.P. (2015) Ltd.</u>			2. Issuer Name and Ticker or Trading Symbol <u>Eloxx Pharmaceuticals, Inc. [ ELOX ]</u>		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)	
(Last) (First) (Middle) <u>C/O ELOXX PHARMACEUTICALS, INC.</u> <u>950 WINTER STREET, 4TH FLOOR NORTH</u>			3. Date of Earliest Transaction (Month/Day/Year) <u>04/30/2018</u>			
(Street) <u>WALTHAM MA 02451</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)			
(City) (State) (Zip)					6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/30/2018		P <sup>(1)</sup>		84,041	A	\$9.75	468,585	I	By Pontifax Investment Fund <sup>(2)</sup>
Common Stock	04/30/2018		P <sup>(1)</sup>		172,626	A	\$9.75	962,504	I	By Pontifax Investment Fund <sup>(3)</sup>
Common Stock	04/30/2018		P <sup>(1)</sup>		93,333	A	\$9.75	520,396	I	By Pontifax Investment Fund <sup>(4)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	V	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>Pontifax Management 4 G.P. (2015) Ltd.</u>	
(Last) (First) (Middle) <u>C/O ELOXX PHARMACEUTICALS, INC.</u> <u>950 WINTER STREET, 4TH FLOOR NORTH</u>	
(Street) <u>WALTHAM MA 02451</u>	
(City) (State) (Zip)	
1. Name and Address of Reporting Person* <u>Pontifax (China) IV L.P.</u>	
(Last) (First) (Middle) <u>C/O ELOXX PHARMACEUTICALS, INC.</u> <u>950 WINTER STREET, 4TH FLOOR NORTH</u>	

1. Reflects the purchase of share

1. Reflects the purchase of shares in the follow-on offering of Common Stock of Elox Pharmaceuticals, Inc. that closed on April 30, 2018.
2. Represents shares of the Issuer held by Pontifax (Cayman) IV L.P. ("Cayman IV"). Pontifax IV GP L.P. ("Pontifax IV") is the general partner of Cayman IV. Pontifax Management 4 G.P. (2015) Ltd. ("Management 4") is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Cayman IV. Each of Management 4, Pontifax IV and Cayman IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
3. Represents shares of the Issuer held by Pontifax (Israel) IV, L.P. ("Israel IV"). Pontifax IV is the general partner of Israel IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by Israel IV. Each of Management 4, Pontifax IV and Israel IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.
4. Represents shares of the Issuer held by Pontifax (China) IV L.P. ("China IV"). Pontifax IV GP L.P. is the general partner of China IV. Management 4 is the general partner of Pontifax IV. As a result, each of Management 4 and Pontifax IV may be deemed to share voting and dispositive power with respect to the shares held by China IV. Each of Management 4, Pontifax IV and China IV disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of the shares in this report shall not be deemed to be an admission of beneficial ownership of the reported shares for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise.

<u>Pontifax Management 4 G.P.</u> <u>(2015) Ltd. /s/ Gregory</u> <u>Weaver, Attorney in Fact on</u> <u>behalf of Tomer Kariv, Chief</u> <u>Executive Officer</u>	<u>05/01/2018</u>
<u>Pontifax (China) IV L.P. /s/</u> <u>Gregory Weaver, Attorney in</u> <u>Fact on behalf of Tomer Kariv,</u> <u>Chief Executive Officer</u>	<u>05/01/2018</u>
<u>Pontifax (Cayman) IV L.P. /s/</u> <u>Gregory Weaver, Attorney in</u> <u>Fact on behalf of Tomer Kariv,</u> <u>Chief Executive Officer</u>	<u>05/01/2018</u>
<u>Pontifax (Israel) IV, L.P. /s/</u> <u>Gregory Weaver, Attorney in</u> <u>Fact on behalf of Tomer Kariv,</u> <u>Chief Executive Officer</u>	<u>05/01/2018</u>
<u>Pontifax IV GP L.P. /s/</u>	<u>05/01/2018</u>

[Gregory Weaver, Attorney in  
Fact on behalf of Tomer Kariy,  
Chief Executive Officer](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**